ITHACA, N.Y.–(BUSINESS WIRE)–AvantGuard, Inc., a biotechnology company developing next-generation antimicrobial technologies inspired by the human immune system, today announced a peer-reviewed study demonstrating that its AVA-003 compound significantly outperformed chlorhexidine gluconate (CHG), the current standard-of-care agent for decolonizing skin of Candida auris (recently reclassified as Candidozyma auris), in a validated mouse model. Conducted independently at Case Western Reserve Uni